论文部分内容阅读
目的拟证实绝经后骨质疏松主要是通过降钙素基因多肽(CGRP)介导,探讨水蛭素对绝经后骨质疏松患者血清CGRP的影响。方法选取60例绝经后骨质疏松患者为试验组,测定血清CGRP水平,并与60例健康青年女性(对照组)血清CGRP水平对比;将60例绝经后骨质疏松患者随机分为3组(各20例)并分别给予脉血康胶囊1粒/次、3次/d,脉血康胶囊2粒/次、3次/d,脉血康胶囊3粒/次、3次/d,连续给药6个月。疗程结束时比较血清CGRP水平。所有患者在服药前、后均须监测血常规,肝、肾功能,凝血四项等指标以评价药物安全性。结果试验组患者血清CGRP水平(173.28±10.65)ng/L明显低于对照组患者的(232.05±3.61)ng/L,差异有统计学意义(P<0.01)。各试验组治疗后血清CGRP水平均较治疗前升高,且治疗后组间比较,差异有统计学意义(P<0.01)。结论水蛭素可提高绝经后骨质疏松患者血清CGRP水平且呈剂量依赖性。
Objective To confirm that postmenopausal osteoporosis is mainly mediated by calcitonin gene polypeptide (CGRP) and to explore the effect of hirudin on serum CGRP in postmenopausal osteoporosis patients. Methods Sixty postmenopausal osteoporosis patients were selected as experimental group, serum CGRP levels were measured and compared with serum CGRP levels in 60 healthy young women (control group); 60 patients with postmenopausal osteoporosis were randomly divided into three groups 20 cases in each group) .Meanwhile, 1 capsule of Xueweikang capsule, 3 capsules / day, 2 capsules of Maiqikang capsule, 3 capsules / time, 3 capsules of Maiweikang capsule, 3 capsules / Administered for 6 months. Serum CGRP levels were compared at the end of treatment. All patients must be monitored before and after taking blood, liver, kidney function, coagulation and other four indicators to evaluate drug safety. Results The level of serum CGRP in the experimental group was significantly lower than that in the control group (173.28 ± 10.65 ng / L, 232.05 ± 3.61 ng / L, P <0.01). Serum CGRP levels in each experimental group were significantly higher than those before treatment, and there was significant difference between the two groups after treatment (P <0.01). Conclusions Hirudin can increase the level of serum CGRP in patients with postmenopausal osteoporosis in a dose-dependent manner.